New hope for kids with rare tumor disorder: drug shows promise in Real-World study

NCT ID NCT06175637

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 26 times

Summary

This study looks at how safe and effective the drug selumetinib is for children aged 3 to 16 with a rare genetic condition (NF1) that causes painful, non-cancerous tumors. About 80-100 kids in China will be followed for 2 years while taking the medication. The goal is to see if the drug shrinks tumors and improves symptoms in everyday medical practice.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROFIBROMA, PLEXIFORM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Research Site

    Beijing, Beijing Municipality, China

  • Research Site

    Chongqing, Chongqing Municipality, China

  • Research Site

    Lanzhou, Gansu, China

  • Research Site

    Guangzhou, Guangdong, China

  • Research Site

    Shenzhen, Guangdong, China

  • Research Site

    Nanning, Guangxi, China

  • Research Site

    Guiyang, Guizhou, China

  • Research Site

    Shijiazhuang, Hebei, China

  • Research Site

    Zhengzhou, Henan, China

  • Research Site

    Wuhan, Hubei, China

  • Research Site

    Changsha, Hunan, China

  • Research Site

    Nanjing, Jiangsu, China

  • Research Site

    Suzhou, Jiangsu, China

  • Research Site

    Nanchang, Jiangxi, China

  • Research Site

    Shenyang, Liaoning, China

  • Research Site

    Jinan, Shandong, China

  • Research Site

    Shanghai, Shanghai Municipality, China

  • Research Site

    Taiyuan, Shanxi, China

  • Research Site

    Xi’an, Shanxi, China

  • Research Site

    Chengdu, Sichuan, China

  • Research Site

    Tianjin, Tianjin Municipality, China

  • Research Site

    Kunming, Yunnan, China

  • Research Site

    Hangzhou, Zhejiang, China

  • Research Site

    Wenzhou, Zhejiang, China

  • Research Site

    Nanjing, China

Conditions

Explore the condition pages connected to this study.